Let's Talk

Category: Uncategorized

  • AI in Drug Discovery

    All Blog Posts AI agents and drug discovery Life Sciences

    AI Agents, Data Integration, and the Future of Drug Discovery

    Versetal Insights · Following the SIM Boston Life Sciences CIO Roundtable

    Learn how AI agents, data integration, and governed workflows help life sciences teams improve drug discovery, reduce research friction, and support better R&D decisions.

    Drug discovery has more data, more tools, and more computational power than ever. Yet Life Sciences teams still face high development costs, long timelines, fragmented workflows, compliance pressure, and limited visibility across research operations.

    Following Stacey Fernandes’ participation in the SIM Boston Life Sciences CIO Roundtable, four themes stood out:

    • Drug discovery needs stronger target validation earlier.
    • Data integration remains a major R&D bottleneck.
    • AI agents need trusted tools, governed data, and defined workflows.
    • Collaborative AI needs human oversight, transparency, and control.

    Together, these themes point to a practical future for AI in life sciences. AI should not replace scientists, bypass governance, or become another disconnected tool. It should support better research decisions, stronger workflow consistency, and faster access to trusted insight.

    The Attrition Problem: Drug Discovery Needs Better Validation Earlier

    Drug development takes over a decade and billions of dollars. Even after years of work and investment, about 90% of candidates fail due to efficacy or safety issues. For life sciences leaders, this creates pressure to improve validation earlier in the process. The issue is not only speed. It is signal quality.

    Research teams need stronger ways to connect data across functional genomics, translational research, clinical medicine, lab operations, scientific literature, and experimental evidence. When this data remains fragmented, teams lose early visibility. Patterns stay hidden. Assumptions move forward unchecked. Risk builds until later stages, when failure becomes more expensive.

    AI has a role in this work, but it does not fix weak data foundations on its own. It needs trusted data, clear workflow structure, traceable reasoning, and scientific review.

    The Integration Bottleneck: More Data Does Not Mean Better Decisions

    Life sciences organizations do not lack data. They lack connected, trusted, usable data. Research, clinical, regulatory, and operational data often sit across different systems, teams, and workflows. The result is friction. Teams spend time reconciling sources, repeating analysis, searching for context, and questioning which source to trust.

    Integration is not only technical. It also involves governance, auditability, access control, workflow alignment, data ownership, cross-functional accountability, and compliance requirements. This matters even more when AI enters the workflow. AI systems need clean access to trusted sources, defined boundaries, reviewable steps, and audit paths. Without this structure, AI creates more work instead of better decisions.

    Strong integration gives AI a better operating environment. It also gives scientists, data leaders, IT teams, and compliance stakeholders a shared foundation for review. Data integration is not plumbing. It is the base layer for governed R&D.

    The AI Agent Solution: Better Systems Around the Model

    Large language models become more useful in life sciences when paired with specialized tools, trusted data sources, and defined workflows. The model alone is not the strategy. The operating system around the model matters.

    AI agents help support complex, multi-step research tasks by working within structured processes. They help teams:

    • Search trusted sources
    • Compare findings
    • Summarize evidence
    • Follow defined workflows
    • Document reasoning paths
    • Support decision-making

    This does not replace scientists. It supports them. The near-term value sits in productivity, consistency, and decision support. For example, an AI agent connected to approved bioinformatics tools and governed datasets might help a research team review known pathways, compare evidence, summarize findings, and flag gaps for expert review. The scientist still decides. The workflow becomes more consistent. The review path becomes clearer.

    In life sciences, useful AI is not the loudest model. It is the system built around trusted data, workflow discipline, clear permissions, scientific oversight, reviewable output, documented decisions, and compliance alignment.

    Collaborative AI: Multiagent Systems Need Human Oversight

    The future of AI in life sciences is not one model doing everything. It is specialized agents working together under human oversight. A multiagent system might include one agent for data retrieval, another for literature review, another for pathway comparison, another for workflow documentation, and another for compliance support.

    Used with discipline, collaborative AI helps teams connect data across functions, reduce manual coordination, improve consistency, support research tasks, preserve review points, strengthen documentation, and keep humans in control. The human role stays central. For regulated life sciences teams, governance is not a finishing touch. It needs to sit inside the workflow from the start.

    A Practical Path Forward

    AI in drug discovery is not only a model selection issue. It is a data, workflow, governance, and operating model issue. Before scaling AI agents across R&D, life sciences leaders should ask:

    • Which data sources are trusted?
    • Which workflows create the most friction?
    • Where does human review occur?
    • Who owns governance?
    • How will decisions get documented?
    • Which systems need integration?
    • How will auditability work?
    • Which use cases create measurable value?

    Life sciences organizations do not need sweeping transformation on day one. They need focused use cases tied to real operating friction. Start with one high-value research workflow. Map the data sources involved. Identify trusted systems of record. Define user roles and access rules. Document human review points. Establish audit paths. Test AI agent support in a controlled setting. Measure productivity, consistency, and decision quality.

    AI agents hold promise for life sciences, but the strongest results will come from better validation, stronger integration, governed workflows, and human oversight. That is how life sciences teams move faster while protecting trust, compliance, and scientific rigor.

    Building AI-ready infrastructure for Life Sciences?

    Versetal helps life sciences organizations design governed data foundations, deploy AI with traceability and compliance, and run the environment 24×7.

    Talk to an architect

  • The AI Execution Gap

    All Blog Posts AI execution gap AI & Data

    The AI Execution Gap: Why Organizations Struggle to Turn AI Ideas Into Business Value

    Versetal Insights

    Why AI pilots stall and how organizations build the data, security, governance, and infrastructure foundation needed for measurable AI value.

    Mid-sized organizations do not have an AI interest problem. They have an execution problem.

    Leaders see the promise: faster decisions, smarter automation, stronger forecasting, lower risk and better use of data. But many AI efforts stall before they create measurable business value because the environment underneath them is not ready.

    Data lives across disconnected systems. Security and governance questions slow adoption. Legacy applications limit integration. IT teams already manage infrastructure, cybersecurity, support, compliance, vendors and daily operations. Then AI gets added to the pile. That is the AI execution gap.

    It is the space between ambition and impact. Organizations know AI has value, but they struggle to move from interest to execution because the foundation does not support secure, trusted, repeatable use. Closing the gap does not start with another tool demo. It starts with a clear view of whether the business has the data, systems, controls, ownership and operating model needed to turn AI ideas into results.

    Why AI Pilots Stall

    AI conversations often jump straight to outcomes.

    Faster reporting. Better forecasts. Lower risk. More automation. Stronger customer insight. Those goals matter, but they hide the work underneath.

    In many organizations, data sits across ERP systems, CRM platforms, finance tools, spreadsheets, cloud applications, legacy databases and manual workflows. Some data is incomplete. Some conflicts across systems. Some arrives too late to support decisions. AI does not fix poor data. It exposes it.

    Legacy systems create more friction. Many companies run a mix of older platforms, newer cloud tools, vendor applications, custom workflows and manual processes. When systems were not designed to work together, AI projects inherit the mess:

    • Data access takes too long
    • Reporting lacks consistency
    • Integration slows progress
    • Security reviews delay adoption
    • Teams disagree on the source of truth
    • Outputs lack trust
    • Workflow ownership remains unclear

    Ownership becomes another barrier. AI touches business teams, IT, security, data, applications, finance, operations, compliance and executive leadership. When no one owns the full path from use case to outcome, projects lose momentum. Pilots happen. Executives ask for progress. Then the initiative gets trapped between “promising” and “not ready to scale.”

    The Real Barrier Is Readiness

    For most organizations, AI barriers are practical.

    Security is one of the biggest.

    Organizations want smarter use of data, but more access creates more exposure. Sensitive customer, employee, supplier, financial, operational, research and regulated data all need controls. Without governance, monitoring and access management, AI introduces risk instead of reducing it.

    Trust is another issue.

    If teams do not trust the data, they will not trust AI outputs. This matters because AI recommendations often influence decisions tied to cost, quality, risk, compliance, production, customer commitments and leadership reporting.

    Skills and bandwidth also matter.

    Internal IT teams already carry a large workload. Adding AI strategy, data architecture, governance, workflow design and adoption planning creates strain fast.

    Many organizations also start too big.

    They try to define an enterprise-wide AI strategy before proving one focused use case. Progress improves when teams start with a business problem, assess readiness, fix the foundation and scale from there.

    Start With the Business Problem

    The best starting point is not the model. It is the business problem. An organization does not need “AI for the business.” It needs a defined use case tied to measurable value. Examples include:

    • Reduce reporting delays
    • Improve demand forecasting
    • Identify operational bottlenecks
    • Strengthen compliance visibility
    • Automate manual review steps
    • Improve customer response time
    • Detect risk patterns earlier
    • Support root cause analysis

    Each use case needs direct answers: What decision needs improvement? What data supports it? Which systems hold the data? Who owns the workflow? What risks apply? Who validates the output? What defines success? What action follows the recommendation? AI output has little value when no one knows what happens next.

    How the Gap Shows Up Across Industries

    AI execution looks different across industries, but the pattern repeats. The business sees opportunity. The technology environment exposes friction.

    In Manufacturing, AI readiness often depends on operational data, plant floor systems, ERP integration, quality workflows, maintenance records and uptime risk. A predictive maintenance use case might stall because machine data, maintenance history, parts inventory and work orders live in separate systems. Before AI creates value, manufacturers need connected data, stable infrastructure, secure access and clear ownership for acting on recommendations.

    In Life Sciences, AI readiness often centers on governance, compliance, validation, access control, auditability and secure collaboration across research, clinical, quality, regulatory and commercial teams. A clinical operations or quality use case might stall if data ownership is unclear, workflows lack controls, or outputs lack review and validation.

    A Practical Path Forward

    Organizations do not need to chase every AI trend. They need a practical path from idea to measurable execution. Start with one use case tied to cost, risk, speed, quality, visibility, compliance, or performance. Map the data. Assess the systems. Define governance. Secure access. Assign business ownership. Pilot with measured outcomes. Scale after proof.

    This turns AI from vague ambition into an operating plan.

    Takeaway

    The AI execution gap is not a sign organizations lack ambition. It is a sign AI needs more than ambition. Organizations move forward when they stop treating AI as a standalone tool and start treating it as part of a connected operating environment. Progress depends on aligning data, security, applications, infrastructure, governance, ownership and support around business use cases. Before launching another AI pilot, assess the foundation underneath it.

    Ready to assess your AI readiness?

    Versetal helps organizations evaluate AI readiness across data, security, applications, infrastructure, governance and operational support, then build a practical roadmap from idea to execution.

    Book a Jumpstart Workshop

  • Research Continuity

    All Blog Posts Research continuity biotech Biotech / Security

    Protecting Research Continuity and Regulated Data as Biotech Teams Scale Trials and Hybrid Lab Operations

    Versetal Insights

    As biotech teams scale, maintaining research continuity requires mapping critical workflows, securing hybrid access, and building operational resilience to protect regulated data and ensure uninterrupted innovation in a complex environment.

    Biotech organizations are under pressure to move faster without losing control. As trials expand, lab environments become more distributed, and teams work across sites and systems, the risk of disruption grows. Research continuity depends on more than uptime. It depends on secure access to data, resilient infrastructure, clear operational processes, and the ability to respond quickly when something goes wrong.

    Many biotech teams are balancing growth with tighter oversight. They need to protect regulated data, support hybrid lab operations, and keep research moving even as complexity increases. The good news is that practical steps can reduce risk without slowing innovation. The key is to focus on the systems, workflows, and security controls that matter most to day-to-day research operations.

    Map Critical Research Workflows Before Expanding

    When trials scale quickly, small gaps in process can turn into major delays. Before adding new sites, users, devices, or applications, biotech leaders should identify the workflows that are most critical to research continuity. That includes sample tracking, lab system access, data transfers, collaboration between research and clinical teams, and the storage of regulated information.

    Start by asking a few direct questions. Which systems are essential for daily lab operations? Where does regulated data enter, move, and get stored? Which teams need access, and from where? What would happen if a key application, network connection, or file repository became unavailable for several hours?

    This kind of mapping helps teams prioritize protection where it matters most. It also reveals dependencies that are easy to miss in a hybrid environment. A trial may rely on cloud platforms, on-prem lab systems, third-party partners, and remote users all at once. If one connection point fails or is misconfigured, the impact can spread quickly.

    By documenting critical workflows early, biotech organizations can make smarter decisions about access controls, backup priorities, incident response planning, and infrastructure investments. It is much easier to secure and support growth when the business knows exactly what must stay available.

    Strengthen Access, Visibility, and Data Protection Across Hybrid Labs

    Hybrid lab operations create flexibility, but they also expand the attack surface. Researchers, clinical teams, vendors, and external partners may all need access to systems and data from different locations. That makes identity, endpoint security, and network visibility especially important.

    A strong starting point is role-based access. Users should have access only to the systems and data they need for their work. As teams grow and trial activity changes, access should be reviewed regularly so permissions do not accumulate over time. Multi-factor authentication, device management, and secure remote access should also be standard for any environment handling regulated data.

    Visibility matters just as much as access control. Security and IT teams need to know what devices are connecting, what applications are being used, and where sensitive data is moving. In many biotech environments, risk builds quietly through shadow IT, unmanaged endpoints, or legacy systems that remain connected because they support a niche but important workflow.

    Data protection should be designed around both compliance and continuity. That means classifying sensitive data, encrypting it appropriately, monitoring for unusual activity, and ensuring backups are reliable and recoverable. For biotech teams, the goal is not only to prevent unauthorized access. It is also to make sure research data remains intact, available, and defensible when timelines are tight and scrutiny is high.

    Build Operational Resilience

    Security controls alone do not guarantee continuity. Biotech teams also need operational resilience. As trials and lab operations scale, the organization should be ready for common disruptions such as ransomware, system outages, vendor issues, accidental deletion, and network instability between sites.

    One practical step is to review recovery readiness for the systems that support active research. Backups should be tested, recovery expectations should be realistic, and teams should know who is responsible for decision-making during an incident. If a lab information system or collaboration platform goes down, every minute spent clarifying ownership adds to the disruption.

    It is also important to align security operations with infrastructure operations. A suspicious login, a failing network segment, and a storage issue may seem like separate events, but in practice they can affect the same research workflow. Coordinated monitoring and response help teams identify issues faster and reduce downtime.

    Biotech organizations often benefit from a consulting-led approach here. Rather than treating security, infrastructure, and application support as separate conversations, they can evaluate how these areas work together to support research outcomes. That is especially valuable during periods of rapid change, when internal teams are stretched and priorities shift week to week.

    The most resilient organizations do not wait for a major incident to test their operating model. They review dependencies, validate response plans, and close visibility gaps before growth exposes them. That preparation helps protect both the pace of research and the integrity of regulated data.

    Versetal’s Role

    As biotech teams scale trials and support hybrid lab operations, protecting research continuity requires a broader view than basic IT support. It takes clear workflow mapping, disciplined access and data protection, and coordinated operational resilience across security and infrastructure. Organizations that address these areas now will be better positioned to keep research moving, reduce disruption, and protect regulated data throughout the quarter. Versetal helps organizations take that practical, connected approach with 24×7 U.S.-based Security Operations and Network Operations backed by experts across Security, Data & AI, Applications, and Infrastructure.

    Scaling trials? Let’s review your continuity posture.

    Versetal provides 24×7 U.S.-based SOC and NOC, GxP-aligned cloud foundations, and coordinated security and infrastructure operations for biotech and life sciences organizations.

    Start a conversation